Show simple item record

dc.contributor.authorRush, Hannah L
dc.contributor.authorMurphy, Laura
dc.contributor.authorMorgans, Alicia K
dc.contributor.authorClarke, Noel W
dc.contributor.authorCook, Adrian D
dc.contributor.authorAttard, Gerhardt
dc.contributor.authorMacnair, Archie
dc.contributor.authorDearnaley, David P
dc.contributor.authorParker, Christopher C
dc.contributor.authorRussell, J Martin
dc.contributor.authorGillessen, Silke
dc.contributor.authorMatheson, David
dc.contributor.authorMillman, Robin
dc.contributor.authorBrawley, Christopher D
dc.contributor.authorPugh, Cheryl
dc.contributor.authorTanguay, Jacob S
dc.contributor.authorJones, Robert J
dc.contributor.authorWagstaff, John
dc.contributor.authorRudman, Sarah
dc.contributor.authorO'Sullivan, Joe M
dc.contributor.authorGale, Joanna
dc.contributor.authorBirtle, Alison
dc.contributor.authorProtheroe, Andrew
dc.contributor.authorGray, Emma
dc.contributor.authorPerna, Carla
dc.contributor.authorTolan, Shaun
dc.contributor.authorMcPhail, Neil
dc.contributor.authorMalik, Zaf I
dc.contributor.authorVengalil, Salil
dc.contributor.authorFackrell, David
dc.contributor.authorHoskin, Peter
dc.contributor.authorSydes, Matthew R
dc.contributor.authorChowdhury, Simon
dc.contributor.authorGilbert, Duncan C
dc.contributor.authorParmar, Mahesh KB
dc.contributor.authorJames, Nicholas D
dc.contributor.authorLangley, Ruth E
dc.date.accessioned2021-11-12T13:41:20Z
dc.date.available2021-11-12T13:41:20Z
dc.date.issued2021-11-10
dc.identifier.citationRush, H., Murphy, L., Morgans, A. K., Clarke, N. W. et al (2021) Quality of Life in men with prostate cancer randomly allocated to receive Docetaxel or Abiraterone in the STAMPEDE Trial, Journal of Clinical Oncology. DOI: 10.1200/JCO.21.00728.en
dc.identifier.issn0732-183Xen
dc.identifier.doi10.1200/jco.21.00728en
dc.identifier.urihttp://hdl.handle.net/2436/624443
dc.descriptionThis is a copy of an article published by American Society of Clinical Oncology in Journal of Clinical Oncology on 10/11/2021, available online: https://ascopubs.org/doi/abs/10.1200/JCO.21.00728 For re-use please see the publisher's terms and conditions.en
dc.description.abstractPURPOSE Docetaxel and abiraterone acetate plus prednisone or prednisolone (AAP) both improve survival when commenced alongside standard of care (SOC) androgen deprivation therapy in locally advanced or metastatic hormone-sensitive prostate cancer. Thus, patient-reported quality of life (QOL) data may guide treatment choices. METHODS A group of patients within the STAMPEDE trial were contemporaneously enrolled with the possibility of being randomly allocated to receive either docetaxel + SOC or AAP + SOC. A mixed-model assessed QOL in those who had completed at least one QLQ-C30 + PR25 questionnaire. The primary outcome measure was difference in global-QOL (QLQ-C30 Q29&30) between patients allocated to docetaxel + SOC or AAP + SOC over the 2 years after random assignment, with a predefined criterion for clinically meaningful difference of > 4.0 points. Secondary outcome measures included longitudinal comparison of functional domains, pain, and fatigue, plus global-QOL at defined timepoints. RESULTS Five hundred fifteen patients (173 docetaxel + SOC and 342 AAP + SOC) were included. Baseline characteristics, proportion of missing data, and mean baseline global-QOL scores (docetaxel + SOC 77.8 and AAP + SOC 78.0) were similar. Over the 2 years following random assignment, the mean modeled global-QOL score was +3.9 points (95% CI, +0.5 to +7.2; P = .022) higher in patients allocated to AAP + SOC. Global-QOL was higher for patients allocated to AAP + SOC over the first year (+5.7 points, 95% CI, +3.0 to +8.5; P < .001), particularly at 12 (+7.0 points, 95% CI, +3.0 to +11.0; P = .001) and 24 weeks (+8.3 points, 95% CI, +4.0 to +12.6; P < .001). CONCLUSION Patient-reported QOL was superior for patients allocated to receive AAP + SOC, compared with docetaxel + SOC over a 2-year period, narrowly missing the predefined value for clinical significance. Patients receiving AAP + SOC reported clinically meaningful higher global-QOL scores throughout the first year following random assignment.en
dc.description.sponsorshipThe STAMPEDE trial is sponsored by the UK Medical Research Council (MRC_MC_UU_12023/25) and conducted by the MRC Clinical Trials Unit at UCL. The trial is supported by CRUK (CRUK_A12459), the MRC, the NIHR Clinical Research Network, and the Swiss Group for Clinical Cancer Research (SAKK). P.J.H. is supported by NIHR Manchester Biomedical Research Center. The trial also receives industry collaboration and support from Novartis, Sanofi-Aventis, Pfizer, Janssen, Clovis Oncology, and Astellas.en
dc.formatapplication/pdfen
dc.languageen
dc.language.isoenen
dc.publisherAmerican Society of Clinical Oncology (ASCO)en
dc.relation.urlhttps://ascopubs.org/doi/abs/10.1200/JCO.21.00728en
dc.titleQuality of Life in men with prostate cancer randomly allocated to receive Docetaxel or Abiraterone in the STAMPEDE Trialen
dc.typeJournal articleen
dc.identifier.eissn1527-7755
dc.identifier.journalJournal of Clinical Oncologyen
dc.date.updated2021-11-11T15:10:20Z
dc.date.accepted2021-10-01
rioxxterms.funderMRCen
rioxxterms.identifier.projectMRC_MC_UU_12023/25en
rioxxterms.identifier.projectCRUK_A12459en
rioxxterms.versionVoRen
dc.description.versionPublished online
refterms.dateFCD2021-11-12T13:38:25Z
refterms.versionFCDVoR


Files in this item

Thumbnail
Name:
Rush_et_al_Quality_of_life_in_ ...
Embargo:
2022-05-10
Size:
826.7Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record